The potential acquisition of Syqe Medical by Phillip Morris represents a significant strategic move for the tobacco giant, signaling its entry into the flourishing marijuana industry. With an initial investment of $130 million to support Syqe’s FDA approval process, followed by a possible $650 million acquisition, this deal can potentially make Syqe one of the largest cannabis companies globally. Moreover, Syqe’s innovative inhaler, utilizing raw cannabis inflorescence, could secure FDA approval, positioning the company as a trailblazer in the medical cannabis sector.
A first-person review of the hemp-derived THC cocktail base I poured at our Cannabis Cup…
Every paper mill in the world still runs on the continuous-web design a Frenchman patented…
A new AI-assisted sci-fi satire from filmmaker Dan Levy Dagerman and the Space Weed Universe…
Spain has increased penalties for electricity theft linked to indoor cannabis cultivation after Endesa reported…
How a 52-year-old first-time grower turned trial and error into a show-stopping harvest The first…
This is the legacy knowledge drain, and it is the quiet catastrophe nobody in the…